HEMODIA
Acquired by
LBO FRANCE
HEMODIA acquired by LBO FRANCE
Target
HEMODIA
Acquirer
LBO FRANCE
Context
Hemodia, a French healthcare group specializing in the production of sterile medical devices, is reorganizing its capital through a second leveraged buyout (LBO) with the investment fund LBO France. Bpifrance and Multicroissance, existing shareholders since the first LBO, are also reinvesting.
The transaction values HEMODIA at an EV/Revenue multiple of LOGIN.
This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
A French healthcare group specializing in the design, assembly, and distribution of sterile medical devices. Its expertise includes customized medical kits (care sets), dialysis connectors, and medical electronics (infusion pumps and enteral nutrition devices).
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with HEMODIA
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.